Preclinical evaluation of multi antigenic HCV DNA vaccine for the prevention of Hepatitis C virus infection

[1]  R. Finch,et al.  Hepatitis C Virus Infection , 2015 .

[2]  Michael Dallas,et al.  Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial , 2015, The Lancet.

[3]  J. Feld,et al.  Hepatitis C virus infection , 2015, Canadian Medical Association Journal.

[4]  C. Walker,et al.  Hepatitis C virus: why do we need a vaccine to prevent a curable persistent infection? , 2015, Current opinion in immunology.

[5]  Nisha A. Viswan,et al.  Correlation between Genetic Variations and Serum Level of Interleukin 28B with Virus Genotypes and Disease Progression in Chronic Hepatitis C Virus Infection , 2015, Journal of immunology research.

[6]  Mark M. Davis,et al.  A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory , 2014, Science Translational Medicine.

[7]  G. Kukolj,et al.  Restoration of HCV-specific CD8+ T cell function by interferon-free therapy. , 2014, Journal of hepatology.

[8]  Janet J. Hamilton,et al.  Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  N. Sardesai,et al.  Strong HCV NS3/4a, NS4b, NS5a, NS5b-specific cellular immune responses induced in Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine , 2014, Human vaccines & immunotherapeutics.

[10]  N. Shoukry,et al.  Protective Immunity Against Hepatitis C: Many Shades of Gray , 2014, Front. Immunol..

[11]  C. Stedman,et al.  Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. , 2014, Gastroenterology.

[12]  H. Mo,et al.  Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial , 2014, The Lancet.

[13]  Yan Zhou,et al.  Will There Be a Vaccine to Prevent HCV Infection? , 2014, Seminars in Liver Disease.

[14]  D. Weiner,et al.  Synthetic DNA Vaccines: Improved Vaccine Potency by Electroporation and Co-Delivered Genetic Adjuvants , 2013, Front. Immunol..

[15]  J. Kublin,et al.  Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. , 2013, The Journal of infectious diseases.

[16]  K. Reddy,et al.  A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus Infection , 2013, PloS one.

[17]  G. Lauer.  Immune responses to hepatitis C virus (HCV) infection and the prospects for an effective HCV vaccine or immunotherapies. , 2013, The Journal of infectious diseases.

[18]  T. Pilot‐Matias,et al.  Exploratory study of oral combination antiviral therapy for hepatitis C. , 2013, The New England journal of medicine.

[19]  D. Weiner,et al.  Induction of Intrahepatic HCV NS4B, NS5A and NS5B-Specific Cellular Immune Responses following Peripheral Immunization , 2012, PloS one.

[20]  N. Sardesai,et al.  Immunotherapy Against HPV16/18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses , 2012, Science Translational Medicine.

[21]  L. M. Conlon,et al.  Many shades of gray. , 2012, Nursing.

[22]  N. Sardesai,et al.  Hepatitis C virus NS3/NS4A DNA vaccine induces multiepitope T cell responses in rhesus macaques mimicking human immune responses [corrected]. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  D. Weiner,et al.  Peripheral immunization induces functional intrahepatic Hepatitis C specific immunity following selective retention of vaccine-specific CD8 T cells by the liver , 2011, Human vaccines.

[24]  L. Davis,et al.  IL-12 selectively programs effector pathways that are stably expressed in human CD8+ effector memory T cells in vivo. , 2011, Blood.

[25]  D. Holtzman,et al.  Hepatitis C Virus Infection Among Adolescents and Young Adults—Massachusetts, 2002–2009 , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[26]  E. Keeffe,et al.  IL-28B As a Predictor of Sustained Virologic Response in Patients with Chronic Hepatitis C Virus Infection. , 2011, Gastroenterology & hepatology.

[27]  M. Houghton.  Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses , 2011, Immunological reviews.

[28]  H. Dahari,et al.  Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins. , 2010, Gastroenterology.

[29]  N. Sardesai,et al.  Unique Th1/Th2 Phenotypes Induced during Priming and Memory Phases by Use of Interleukin-12 (IL-12) or IL-28B Vaccine Adjuvants in Rhesus Macaques , 2010, Clinical and Vaccine Immunology.

[30]  William M. Lee,et al.  Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. , 2010, Gastroenterology.

[31]  D. Weiner,et al.  Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. , 2009, Blood.

[32]  Michele A. Kutzler,et al.  DNA vaccines: ready for prime time? , 2008, Nature Reviews Genetics.

[33]  A. Folgori,et al.  A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees , 2006, Nature Medicine.

[34]  C. Walker,et al.  Adaptive immune responses in acute and chronic hepatitis C virus infection , 2005, Nature.

[35]  Charles M. Rice,et al.  HCV Persistence and Immune Evasion in the Absence of Memory T Cell Help , 2003, Science.

[36]  J. Ghrayeb,et al.  Memory CD8+ T Cells Are Required for Protection from Persistent Hepatitis C Virus Infection , 2003, The Journal of experimental medicine.

[37]  C. Rice,et al.  Previously Infected and Recovered Chimpanzees Exhibit Rapid Responses That Control Hepatitis C Virus Replication upon Rechallenge , 2002, Journal of Virology.

[38]  M. Houghton,et al.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. , 1989, Science.

[39]  N. Sardesai,et al.  Hepatitis C Virus NS3/NS4A DNA Vaccine Induces Multiepitope T Cell Responses in Rhesus Macaques Mimicking Human Immune Responses. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.